UY32011A - Compuestos de fenantrenona, composiciones y métodos - Google Patents

Compuestos de fenantrenona, composiciones y métodos

Info

Publication number
UY32011A
UY32011A UY0001032011A UY32011A UY32011A UY 32011 A UY32011 A UY 32011A UY 0001032011 A UY0001032011 A UY 0001032011A UY 32011 A UY32011 A UY 32011A UY 32011 A UY32011 A UY 32011A
Authority
UY
Uruguay
Prior art keywords
compounds
fenantrenone
compositions
methods
salts
Prior art date
Application number
UY0001032011A
Other languages
English (en)
Inventor
Paul Vincent Rucker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY32011A publication Critical patent/UY32011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se dirige a los compuestos de fórmula I: o sus sales, que son moduladores del receptor glucocorticoide. Los compuestos y sales de la invención son útiles en el tratamiento de afecciones mediadas por la actividad del receptor glucocorticoide.
UY0001032011A 2008-07-28 2009-07-28 Compuestos de fenantrenona, composiciones y métodos UY32011A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8409508P 2008-07-28 2008-07-28

Publications (1)

Publication Number Publication Date
UY32011A true UY32011A (es) 2010-02-26

Family

ID=41037773

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032011A UY32011A (es) 2008-07-28 2009-07-28 Compuestos de fenantrenona, composiciones y métodos

Country Status (39)

Country Link
US (2) US8148409B2 (es)
EP (1) EP2307375B1 (es)
JP (1) JP4823397B1 (es)
KR (1) KR101377860B1 (es)
CN (1) CN102112446B (es)
AP (1) AP2744A (es)
AR (1) AR072535A1 (es)
AU (1) AU2009278029B2 (es)
BR (1) BRPI0917212A2 (es)
CA (1) CA2729578C (es)
CL (1) CL2011000141A1 (es)
CO (1) CO6290761A2 (es)
CR (1) CR20110012A (es)
CU (1) CU23983B1 (es)
DK (1) DK2307375T3 (es)
DO (1) DOP2011000029A (es)
EA (1) EA018024B1 (es)
EC (1) ECSP11010795A (es)
ES (1) ES2527137T3 (es)
GE (1) GEP20125640B (es)
GT (1) GT201100026A (es)
HK (1) HK1154245A1 (es)
HR (1) HRP20150021T1 (es)
IL (1) IL210492A (es)
MA (1) MA32512B1 (es)
MX (1) MX2011001053A (es)
NI (1) NI201100028A (es)
NZ (1) NZ590559A (es)
PE (1) PE20110559A1 (es)
PL (1) PL2307375T3 (es)
PT (1) PT2307375E (es)
RS (1) RS53747B1 (es)
SI (1) SI2307375T1 (es)
SV (1) SV2011003821A (es)
TW (1) TWI374878B (es)
UA (1) UA99198C2 (es)
UY (1) UY32011A (es)
WO (1) WO2010013158A1 (es)
ZA (1) ZA201101520B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013010576A (es) * 2011-03-15 2014-03-12 Abbvie Inc Moduladores de receptores de hormonas nucleares.
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011018A (es) 1999-04-30 2002-05-06 Pfizer Prod Inc Moduladores del receptor glucocorticoide.
KR100694685B1 (ko) 1999-07-30 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 염기성 항생물질ㆍ무기산염의 제조 방법 및 수산염중간체
ES2262612T3 (es) 2000-10-28 2006-12-01 Pfizer Products Inc. Moduladpres del receptor de glucocorticoides.
EP1201660B1 (en) 2000-10-30 2005-08-31 Pfizer Products Inc. Glucocorticoid receptor modulators
ES2518940T3 (es) * 2002-07-08 2014-11-06 Pfizer Products Inc. Moduladores del receptor de glucocorticoides
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
GB0613836D0 (en) 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
JP5264759B2 (ja) 2006-11-21 2013-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用
JP2010511717A (ja) 2006-12-05 2010-04-15 ニューロジェシックス， インコーポレイテッド プロドラッグおよびその作成ならびに使用方法
PT2114970E (pt) * 2007-02-02 2011-09-22 Pfizer Prod Inc Compostos tricíclicos e sua utilização como moduladores de receptor de glucocorticóide
UZ4378C (en) * 2007-02-02 2011-07-29 Pfizer Prod Inc Tricyclic compounds and their use as glucocorticoid receptor modulators

Also Published As

Publication number Publication date
SI2307375T1 (sl) 2015-02-27
TW201014823A (en) 2010-04-16
US8148409B2 (en) 2012-04-03
RS53747B1 (en) 2015-06-30
CO6290761A2 (es) 2011-06-20
DOP2011000029A (es) 2014-07-31
BRPI0917212A2 (pt) 2015-11-10
US8552035B2 (en) 2013-10-08
MA32512B1 (fr) 2011-07-03
CN102112446A (zh) 2011-06-29
UA99198C2 (ru) 2012-07-25
HRP20150021T1 (en) 2015-03-27
HK1154245A1 (en) 2012-04-13
ECSP11010795A (es) 2011-02-28
JP4823397B1 (ja) 2011-11-24
CU23983B1 (es) 2014-03-26
DK2307375T3 (en) 2014-12-08
US20120157502A1 (en) 2012-06-21
EA201100080A1 (ru) 2011-08-30
CR20110012A (es) 2011-02-10
AR072535A1 (es) 2010-09-01
ZA201101520B (en) 2011-10-26
AU2009278029B2 (en) 2012-05-03
WO2010013158A1 (en) 2010-02-04
CU20110020A7 (es) 2011-12-28
TWI374878B (en) 2012-10-21
PT2307375E (pt) 2015-01-14
KR20110022091A (ko) 2011-03-04
IL210492A (en) 2015-04-30
CN102112446B (zh) 2012-10-31
AP2744A (en) 2013-09-30
NZ590559A (en) 2011-09-30
CA2729578A1 (en) 2010-02-04
US20100069444A1 (en) 2010-03-18
AU2009278029A1 (en) 2010-02-04
GEP20125640B (en) 2012-09-10
SV2011003821A (es) 2011-07-28
MX2011001053A (es) 2011-04-21
EA018024B1 (ru) 2013-04-30
IL210492A0 (en) 2011-03-31
JP2011529103A (ja) 2011-12-01
EP2307375B1 (en) 2014-11-19
KR101377860B1 (ko) 2014-03-25
ES2527137T3 (es) 2015-01-21
GT201100026A (es) 2013-12-10
CA2729578C (en) 2014-05-27
PE20110559A1 (es) 2011-08-06
EP2307375A1 (en) 2011-04-13
AP2011005562A0 (en) 2011-02-28
CL2011000141A1 (es) 2011-06-17
PL2307375T3 (pl) 2015-03-31
NI201100028A (es) 2011-08-05

Similar Documents

Publication Publication Date Title
CR10949A (es) Compuestos triciclicos, composiciones y procedimientos
CO7400867A2 (es) Modificador del sabor dulce
ECSP11011493A (es) 1-(piperidin-4-il)-derivados de pirazol como moduladores de gpr 119
CO6361937A2 (es) Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
ECSP10010271A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
UY30052A1 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CO6321288A2 (es) Sales de compuestos inhibidores de vih
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
ECSP11010795A (es) Compuestos de fenantrenona, composiciones y métodos
DOP2009000191A (es) Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides
CU20080116A7 (es) 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas
UY30887A1 (es) Compuestos triciclicos, composiciones y procedimientos
CU20100127A7 (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CU20110054A7 (es) Derivados heteroaril amida y sus usos como glucoquinasa activadores
CU23642B7 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181108